Valeant Pharmaceuticals International Inc

Cornelia Mascio
Giugno 19, 2017

Pictet Asset Management Ltd.'s holdings in Valeant Pharmaceuticals International were worth $1,258,000 as of its most recent SEC filing. Moreover, Alpine Vi Ltd Limited Liability Company has 2.88% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 425,000 shares. Brave Asset Management Inc. purchased a new position in Valeant Pharmaceuticals International during the first quarter worth about $119,000. Public Sector Pension Investment Board increased its stake in Valeant Pharmaceuticals International by 3.1% in the fourth quarter. Point View Wealth Management Inc. now owns 52,896 shares of the specialty pharmaceutical company's stock worth $583,000 after buying an additional 20,447 shares in the last quarter. Endurant Capital Management LP acquired a new position in Valeant Pharmaceuticals International during the first quarter valued at about $221,000. Vanguard Grp invested in 0.01% or 6.36 million shares.

Several analysts have released their opinion on Valeant Pharmaceuticals International, Inc. Morgan Stanley downgraded Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Friday, October 2 to "Equal-Weight" rating.

Bluefin Trading Ltd Co stated it has 3,300 shares or 0% of all its holdings. Valeant Pharmaceuticals Intl has $310 highest and $9 lowest target. The Company operates through two segments: Developed markets and Emerging markets. The firm has a 50-day moving average of $12.26 and a 200-day moving average of $12.99. Valeant Pharmaceuticals International also was the target of unusually large options trading on Friday. Stock investors bought 35,088 put options on the company. The specialty pharmaceutical company reported $2.80 EPS for the quarter, topping the Zacks' consensus estimate of $0.87 by $1.93. The company had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.17 billion. Valeant Pharmaceuticals International had 34 analyst reports since October 20, 2015 according to SRatingsIntel. The business's revenue for the quarter was down 11.1% on a year-over-year basis. During the same period previous year, the company earned ($1.08) earnings per share. Valeant Pharmaceuticals International's quarterly revenue was down 11.1% compared to the same quarter previous year.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and worldwide copyright and trademark legislation. Clearbridge Invests Limited Liability reported 0.05% stake.

VRX has been the subject of a number of research analyst reports. Guggenheim restated a "buy" rating and issued a $55.00 price target on shares of Valeant Pharmaceuticals International in a research report on Tuesday, February 28th. Deutsche Bank AG set a $20.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a "hold" rating in a report on Saturday, January 21st.

Among 4 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 0 have Buy rating, 0 Sell and 4 Hold. Canaccord Genuity set a $19.00 target price on Valeant Pharmaceuticals International and gave the stock a hold rating in a research report on Wednesday, February 22nd. Jefferies Group LLC dropped their price target on shares of Valeant Pharmaceuticals International from $22.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, March 1st. DE SCHUTTER RICHARD U bought 20,000 shares worth $278,000. The shares were acquired at an average cost of $13.90 per share, for a total transaction of $278,000.00. Following the acquisition, the director now directly owns 70,572 shares in the company, valued at approximately $980,950.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Synovus Financial Corporation, Georgia-based fund reported 5 shares.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE